Reporting on Adverse Clinical Events, 2018

DOI: 10.1177/0069477018795149

Keywords: Cannabinoids, Synthetic (206),Clozapine (209),Dabrafenib (211),Denosumab (212),Dietary Supplement (214),Flucloxacillin (217),Furosemide (204),Long-Acting β-Agonists/Corticosteroids, Inhaled (216),Poisonings (205),Sildenafil (210),Tumor Necrosis Factor-α Antagonists (207),Tocilizumab (215),Trametinib (211),Valproic Acid (213),Valsartan (208),Warfarin (217)

Full-Text